Investment Summary

EQT Life Sciences Invests In Visus Therapeutics

On August 10, 2021, growth capital firm EQT Life Sciences invested in life science company Visus Therapeutics

Investment Highlights
  • This is EQT Life Sciences’ 23rd transaction in the Life Science sector.
  • This is EQT Life Sciences’ 9th transaction in the United States.
  • This is EQT Life Sciences’ 1st transaction in Washington.

Investment Summary

Date 2021-08-10
Target Visus Therapeutics
Sector Life Science
Investor(s) EQT Life Sciences
Deal Type Venture

Target

Visus Therapeutics

Seattle, Washington, United States
Visus Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, Visus Therapeutics was founded in 2019 and is based in Seattle, Washington.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

EQT Life Sciences


Category Growth Capital Firm
Founded 1987
PE ASSETS 2.0B USD
Size Large
Type Sector Focused
DESCRIPTION


DEAL STATS #
Overall 39 of 47
Sector (Life Science) 23 of 30
Type (Venture) 33 of 39
State (Washington) 1 of 1
Country (United States) 9 of 11
Year (2021) 7 of 12
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-21 binx health

Cambridge, Massachusetts, United States

binx health is a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop. binx health was founded in 2005 and is based in Cambridge, Massachusetts.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-09 Evommune

Los Altos, California, United States

Evommune is a biopharmaceutical company developing innovative therapies in the area of chronic inflammation, particularly in dermatological conditions. Evommune was founded in 2020 and is based in Los Altos, California.

Buy -